Filing Flows › Crescent Biopharma (CBIO) › Q1 2026
Crescent Biopharma (CBIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 29, 2026
Crescent Biopharma (CBIO) reported revenue of $1.0M for the first quarter 2026 (Q1 2026).
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | — |
| Operating profit | −$24.7M | — | — |
| Net earnings | −$23.3M | — | — |
| Operating cash flow | −$8.9M | — | — |
What changed
Revenue was $1.0M in Q1 2026.
Operating costs exceeded revenue by $24.7M, an operating margin of -2380.1%. The quarter ended with a net loss of $23.3M.
Operating cash flow was −$8.9M. Non-cash charges added back $64K of depreciation and $4.1M of share-based compensation. Working capital and other items added $10.2M. Capital expenditures of $147K exceeded it, leaving free cash flow of −$9.1M.
Questions
What was Crescent Biopharma's revenue in the first quarter 2026?
Crescent Biopharma (CBIO) reported revenue of $1.0M for the first quarter 2026 (Q1 2026).
Source: Crescent Biopharma 10-Q on SEC EDGAR.